-
公开(公告)号：AU2003220260A1
公开(公告)日：2003-10-08
申请号：AU2003220260
申请日：2003-03-14
Applicant: TECHNOLOGY COMMERCIALIZATION
Abstract: A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. One disclosed method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.
-
公开(公告)号：AU2003220260A8
公开(公告)日：2003-10-08
申请号：AU2003220260
申请日：2003-03-14
Applicant: TECHNOLOGY COMMERCIALIZATION
Abstract: A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose, the substance can be used to treat various disorders of a nervous system such as pain, insomnia, anxiety, neurosis, depression, as well as withdrawal symptoms experienced by drug addiction patients, especially for patients addicted to opiate-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. One disclosed method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.
-
公开(公告)号：CA2479214A1
公开(公告)日：2003-10-02
申请号：CA2479214
申请日：2003-03-14
Applicant: TECHNOLOGY COMMERCIALIZATION
Abstract: A substance with sedative effect comprises a therapeutically effective amoun t of a gamma-pyrone such as comenic acid, meconic acid, chelidonic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 5 and 200 mg of active ingredient per kilogram of a body weight of a patient, the substance can be used to treat various neurotic disorders such as insomnia, anxiety, neurosis, depression as well as withdrawal symptoms for drug addiction patients, especially for patients addicted to opioid-based drugs. The substance can be delivered in a number o f ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effecti ve daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.
-
公开(公告)号：EP1485050A4
公开(公告)日：2008-08-13
申请号：EP03716557
申请日：2003-03-14
Applicant: TECHNOLOGY COMMERCIALIZATION
IPC: A61K31/351 , A61K9/22 , A61K9/52 , A61K9/62 , A61K31/35 , A61P25/20 , A61F13/00 , A61K9/14 , A61K47/10 , A61K47/26
CPC classification number: A61K31/35 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0053 , A61K9/0073
-
-
-
Search Results
4
records
(took 0.019 seconds)
